Literature DB >> 25549873

Effective termination of status epilepticus by rational polypharmacy in the lithium-pilocarpine model in rats: Window of opportunity to prevent epilepsy and prediction of epilepsy by biomarkers.

Claudia Brandt1, Kathrin Töllner1, Rebecca Klee1, Sonja Bröer1, Wolfgang Löscher2.   

Abstract

The pilocarpine rat model, in which status epilepticus (SE) leads to epilepsy with spontaneous recurrent seizures (SRS), is widely used to study the mechanisms of epileptogenesis and develop strategies for epilepsy prevention. SE is commonly interrupted after 30-90min by high-dose diazepam or other anticonvulsants to reduce mortality. It is widely believed that SE duration of 30-60min is sufficient to induce hippocampal damage and epilepsy. However, resistance to diazepam develops during SE, so that an SE that is longer than 30min is difficult to terminate, and SE typically recurs several hours after diazepam, thus forming a bias for studies on epileptogenesis or antiepileptogenesis. We developed a drug cocktail, consisting of diazepam, phenobarbital, and scopolamine that allows complete and persistent SE termination in the lithium-pilocarpine model. A number of novel findings were obtained with this cocktail. (a) In contrast to previous reports with incomplete SE suppression, a SE of 60min duration did not induce epilepsy, whereas epilepsy with SRS developed after 90 or 120min SE; (b) by comparing groups of rats with 60 and 90min of SE, development of epilepsy could be predicted by behavioral hyperexcitability and decrease in seizure threshold, indicating that these read-outs are suited as biomarkers of epileptogenesis; (c) CA1 damage was prevented by the cocktail, but rats exhibited cell loss in the dentate hilus, which was related to development of epilepsy. These data demonstrate that the duration of SE needed for induction of epileptogenesis in this model is longer than previously thought.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Diazepam; Pharmacoresistance; Phenobarbital; Scopolamine

Mesh:

Substances:

Year:  2014        PMID: 25549873     DOI: 10.1016/j.nbd.2014.12.015

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  21 in total

1.  Adult neurogenesis in the mouse dentate gyrus protects the hippocampus from neuronal injury following severe seizures.

Authors:  Swati Jain; John J LaFrancois; Justin J Botterill; David Alcantara-Gonzalez; Helen E Scharfman
Journal:  Hippocampus       Date:  2019-01-23       Impact factor: 3.899

2.  Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy.

Authors:  Melissa L Barker-Haliski; Taylor D Heck; E Jill Dahle; Fabiola Vanegas; Timothy H Pruess; Karen S Wilcox; H Steve White
Journal:  Epilepsia       Date:  2016-10-14       Impact factor: 5.864

3.  Urethane attenuates early neuropathology of diisopropylfluorophosphate-induced status epilepticus in rats.

Authors:  Asheebo Rojas; Jennifer Wang; Avery Glover; Raymond Dingledine
Journal:  Neurobiol Dis       Date:  2020-04-10       Impact factor: 5.996

4.  Simultaneous triple therapy for the treatment of status epilepticus.

Authors:  Jerome Niquet; Roger Baldwin; Keith Norman; Lucie Suchomelova; Lucille Lumley; Claude G Wasterlain
Journal:  Neurobiol Dis       Date:  2017-04-29       Impact factor: 5.996

5.  Oxidative Stress Contributes to Status Epilepticus Associated Mortality.

Authors:  Jennifer N Pearson-Smith; Li-Ping Liang; Shane D Rowley; Brian J Day; Manisha Patel
Journal:  Neurochem Res       Date:  2017-05-02       Impact factor: 3.996

6.  Treatment of experimental status epilepticus with synergistic drug combinations.

Authors:  Jerome Niquet; Roger Baldwin; Lucie Suchomelova; Lucille Lumley; Roland Eavey; Claude G Wasterlain
Journal:  Epilepsia       Date:  2017-02-22       Impact factor: 5.864

7.  Deep hypothermia for the treatment of refractory status epilepticus.

Authors:  Jerome Niquet; Roger Baldwin; Michael Gezalian; Claude G Wasterlain
Journal:  Epilepsy Behav       Date:  2015-07-18       Impact factor: 2.937

8.  Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits.

Authors:  Jerome Niquet; Roger Baldwin; Keith Norman; Lucie Suchomelova; Lucille Lumley; Claude G Wasterlain
Journal:  Epilepsia       Date:  2016-08-08       Impact factor: 5.864

9.  Dexmedetomidine stops benzodiazepine-refractory nerve agent-induced status epilepticus.

Authors:  Hilary S McCarren; Julia A Arbutus; Cherish Ardinger; Emily N Dunn; Cecelia E Jackson; John H McDonough
Journal:  Epilepsy Res       Date:  2018-01-31       Impact factor: 3.045

10.  Divergent metabolic substrate utilization in brain during epileptogenesis precedes chronic hypometabolism.

Authors:  Pablo Bascuñana; Mirjam Brackhan; Ina Leiter; Heike Keller; Ina Jahreis; Tobias L Ross; Frank M Bengel; Marion Bankstahl; Jens P Bankstahl
Journal:  J Cereb Blood Flow Metab       Date:  2018-10-30       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.